Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$4.72 USD
-0.45 (-8.70%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $4.73 +0.01 (0.21%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Lyra Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -62.68 | -55.28 | -43.51 | -22.13 | -16.31 |
Depreciation/Amortization & Depletion | -3.22 | 0.58 | 1.00 | 0.10 | 0.03 |
Net Change from Assets/Liabilities | -4.89 | 4.56 | 13.92 | -0.88 | 2.11 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.48 | 6.76 | 2.77 | 1.77 | 0.41 |
Net Cash From Operating Activities | -63.30 | -43.39 | -25.82 | -21.14 | -13.75 |
Property & Equipment | -1.05 | -0.16 | -3.39 | -1.78 | -0.21 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -11.54 | -64.84 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -12.58 | -65.01 | -3.39 | -1.78 | -0.21 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 69.35 | 100.50 | 0.60 | 90.29 | 0.11 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -3.65 | -4.25 | -0.25 | -2.59 | -0.23 |
Net Cash from Financing Activities | 65.69 | 96.26 | 0.36 | 87.70 | -0.12 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -10.20 | -12.13 | -28.85 | 64.79 | -14.08 |
Cash at Beginning of Period | 33.94 | 46.08 | 74.92 | 10.14 | 24.22 |
Cash at End of Period | 23.75 | 33.94 | 46.08 | 74.92 | 10.14 |
Diluted Net EPS | -1.26 | -1.83 | -3.35 | -2.59 | NA |
Fiscal Year End for Lyra Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -62.68 | -47.52 | -31.87 | -16.26 |
Depreciation/Amortization & Depletion | NA | -3.22 | -2.22 | -1.09 | -0.44 |
Net Change from Assets/Liabilities | NA | -4.89 | -0.50 | -1.72 | -0.76 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 7.48 | 6.00 | 4.56 | 1.61 |
Net Cash From Operating Activities | NA | -63.30 | -44.25 | -30.13 | -15.85 |
Property & Equipment | NA | -1.05 | -0.26 | -0.12 | -0.05 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -11.54 | -9.96 | 4.87 | 5.36 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -12.58 | -10.23 | 4.75 | 5.32 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 69.35 | 50.10 | 50.10 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -3.65 | -3.33 | -2.91 | 0.00 |
Net Cash from Financing Activities | NA | 65.69 | 46.77 | 47.19 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -10.20 | -7.70 | 21.81 | -10.53 |
Cash at Beginning of Period | NA | 33.94 | 33.94 | 33.94 | 33.94 |
Cash at End of Period | NA | 23.75 | 26.24 | 55.75 | 23.41 |
Diluted Net EPS | NA | -0.19 | -0.27 | -0.36 | -0.44 |